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PHYSIOPATHOLOGY of organ ￿ brosis is far from
being completely understood, and the ef￿ cacy of
the available therapeutic strategies is disappoint-
ing. We chose pleural disease for further studies
and addressed the questions of which cytokines
are relevant in pleural ￿ brosis and which drugs
might interrupt its development. We screened
pleural effusions for mediators thought to inter-
fere with ￿ brogenesis (transforming growth fac-
tor-b (TGF-b), tumour necrosis factor a (TNFa),
soluble TNF-receptor p55 (sTNF-R)) and corre-
lated the results with patient clinical outcome in
terms of extent of pleural thickenings. We found
pleural thickenings correlated with TGF-b
(P, 0 005) whereas no correlations could be ob-
served with TNFa and sTNF-R. Further, we were
interested in ￿ nding out how TGF-b effects on
￿ broblast growth could be modulated. We found
that pentoxifylline is able to inhibit both ￿ bro-
blast proliferation and collagen synthesis inde-
pendently of the stimulus. We conclude that,
judging from in vitro studies, pentoxifylline
might offer a new approach in the therapy of
pleural as well as pulmonary ￿ brosis.
Key words: Collagen, Fibroblast, Fibrosis, Pent-
oxifylline, Pleural effusion, Therapy, Transforming
growth factor b, Tumour necrosis factor a
Introduction
The normal ￿brotic response to lung tissue
injury is ￿nely controlled. Despite multifactorial
origins, mesenchymal cells migrate to the site of
injury, proliferate and subsequently synthesize
extracellular matrix components.1 Neither the
factors that contribute to limited matrix produc-
tion in wound healing nor those that control
excess or sustained matrix production in ￿bro-
sis have been fully characterized. Cytokines
have been considered highly important in the
development of pulmonary ￿brosis (e.g. platelet
derived growth factor (PDGF), tumour necrosis
factor a (TNFa), transforming growth factor b
(TGF-b)).2 5 A therapeutic breakthrough has,
however, not been forthcoming. Corticosteroids
are still the ￿rst-line therapeutics in pulmonary
￿brosis, even though they improve the course
of disease in only about 25%of cases, and that
to an often disappointing extent.6 Alternative
therapeutic regimen are either toxic, not con-
vincingly effective or have not yet been sub-
jected to suf￿cient study.6
We chose pleural disease for further studies
on the physiopathology of ￿brosis and thera-
peutic intervention strategies. Mesothelial cells
of the pleura, being highly susceptible to harm-
ful events,7 exfoliate and uncover the submeso-
thelial connective tissue. An exudative
in￿ammatory reaction results with the accumu-
lation of ￿uids in the pleural space.8 These
￿uids contain a variety of substances with the
potential to in￿uence cell growth.9,10 Pleural
effusions are most intimately in contact with
extracellular matrix producing submesothelial
connective tissue, so we hypothesized they
might re￿ect the complex mechanisms of in-
￿ammation, wound healing, and development
of pleural ￿brosis. We addressed the question of
whether mediators considered to be causally
involved in ￿brosis of the lungs by either
stimulating matrix synthesis (TGF-b11) or inhibit-
ing cytokines or matrix production (soluble
TNF-receptor p55 (sTNF-R),12 are also physio-
pathologically relevant in pleural ￿brosis.
Having worked out comparative mediator
pro￿les and clinical patient outcomes, we
investigated the effect of the cytokine found to
be relevant (TGF-b) and of pleural effusions, a
material containing a multiplicity of mediators,
on in vitro ￿broblast cultures in order to search
for alternatives to steroid treatment. Screening
various drugs, we chose the xanthine derivative
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Pentoxifylline is a methylxanthine initially pre-
scribed in the therapy of peripheral vascular
disease13 which has been shown to interact
with several cell types including ￿broblasts.14
Our rationale for this choice included the
growing set of data indicating that the intra-
cellular concentration of cyclic adenosine
monophosphate (cAMP) in￿uences ￿broblast
activity.15,16 Pentoxifylline augments cAMP by
inhibiting phosphodiesterase activity16 and acti-
vating adenylate cyclase by inducing prosta-
cyclin17 and has been shown to inhibit
￿broblast collagen, glycosaminoglycan and ￿bro-
nectin synthesis and increase collagenase
activity.18 POF inhibits ￿broblast proliferation
stimulated by platelet-derived growth factor
(PDGF), a further cytokine considered impor-
tant in ￿brosis.19 The drug has also been shown
to modulate in￿ammatory and immune reac-
tions effectively (e.g. inhibition of leukocyte
adhesion, aggregation, degranulation and super-
oxide release and monocyte TNF-a synthesis16).
Thus we assumed that pentoxifylline’s mechan-
ism of action might constitute an effective
therapeutic action in ￿brosis.
In this paper, we provide data on (1) cytokine
concentrations inpleuraleffusions(TGF-b,TNFa,
sTNF-R); (2) pentoxifylline effects on (a) ￿bro-
blast cell proliferation, and (b) ￿broblast colla-
gen synthesis stimulated by pleural effusions
and pure cytokines (TNFa, TGF-b). Concluded
from these in vitro investigations, data is in
favour of a pentoxifylline bene￿t in ￿brosis.
Materials and Methods
Subjects
Unless otherwise indicated, proteins were ana-
lysed in pleural effusions from 49 consecutive
patients suffering from non-carcinomatous
pleurisy. Table 1 lists the pertinent clinical
features and diagnoses. In all cases, thoracent-
esis or thoracoscopy was performed for diag-
nostic reasons. Only pleural ￿uids from the ￿rst
diagnostic or therapeutic pleural intervention
were used in this study. Routine analysis
included the determination of speci￿c weight,
cell differentiation, total protein concentration
and LDHconcentration and subsequent classi￿-
cation as transudates (total protein in pleural
￿uid , 30 g/l, LDH-ratio pleural ￿uid:blood:
, 0 6, or exudates (protein . 30 g/l, LDH-ratio
. 0 6). Further analyses (cytomorphology, im-
munological markers, etc.) were done as appro-
priate. The ￿uids were centrifuged and the
supernatant devoid of cellular components was
stored at 808 Cuntil further investigation.
In 24 of the subjects we were able to do
follow-up studies. Pleural thickenings were mea-
sured using chest X-ray ￿lms or computed
tomography (CT) scans of the thorax made 3± 6
months after diagnosis during follow-up exam-
inations and classi￿ed according to the inter-
national classi￿cation of radiographs of pneu-
moconioses (International Labor Of￿ce (ILO)).20
The results were correlated with the concentra-
tions of TGF-b, TNFa, and sTNF-R in the pleural
effusions.
In seven of the patients, pleural effusions
were co-cultivated ex vivo with a ￿broblast cell
culture. Details of these patients read as follows:
pleural effusions occurred due to heart failure
(patient 1, male, 39 years; patient 2, male, 61
years); due to neutrophil-rich parinfectious
pleurisy (patient 3, male, 57 years); due to
macrophage-rich parinfectious pleurisy (patient
4, male, 38 years; patient 5, male, 61 years), and
due to tuberculosis (patient 6, male, 72 years;
patient 7, male, 39 years).
Assay of transforming growth
factor-b
Measurement of TGF by bioassay (growth in-
hibition of a mink lung epithelial cell line) did
not reveal reproducible results. Thus TGF-b 1
was determined by ELISA in which studies on
recovery and reproducibility showed good re-
sults (Quantikinine, R&D Systems, MN, USA).
Sample preparation included acidi￿cation using
1 mol/l acetic acid to split the molecule off the
protein binding and subsequent dialysis using
Visking membranes (Serva, Germany, exclusion
limit: 8000± 15000 dalton) against phosphate
buffer solution (PBS, Gibco BRL, w/o calcium
magnesium). Thus, both the inactive, latent,
and the active form of TGF-b are detected. The
assay uses a sandwich enzyme immunoassay
technique with a monoclonal antibody against
TGF-b and a detection system using a polyclonal
antibody conjugated to horseradish peroxidase.
Optical density determined in a multiwell scan-
ning spectrophotometer (ELISA-reader, Dyna-
tech MR 5000) at a wavelength of 450 nm
allowed calculation of TGF-b of the samples by
comparison with a standard curve. Lower detec-
tion limit of the assay is at 5 pg/ml.
Assay of tumour necrosis factor a
Sample preparation was not a prerequisite in
this assay. The sandwich immunoassay (Medge-
nix Diagnostics, Belgium) consists of oligoclonal
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tion system conjugated to horseradish peroxi-
dase. It detects total TNFa (i.e. monomeric,
trimeric, receptor-bound, and non-bound TNF).
Concentrations of TNF can be determined by
comparing optical densities of samples with
standard curves. No cross-reactivity has been
reported with tumour necrosis factor b (TNF-b),
interleukin-1 (IL-1), interleukin-2 (IL-2), inter-
feron-a (IFN-a), interferon-b (IFN-b), or inter-
feron-c (IFN-c) (product information Medgenix).
Detection limit of the assay is at 3 pg/ml.
Assay of soluble tumour necrosis
factor receptor p55
This assay was a kind gift of Dr H. Gallati
(Hoffmann-La Roche, Switzerland). Principle of
the assay is a sandwich enzyme immunoassay
technique consisting of a monoclonal TNF-
receptor p55 antibody (mouse) and peroxidase-
conjugated recombinant TNF-a. Concentrations
of unknowns are calculated from optical densi-
ties determined at a wavelength of 450 nm
using a ELISA-reader. Detection limit is 100 pg/
ml. No cross-reactivity with IFN-a, IFN-c, IL-1a,
IL-1b, PDGF-AA, PDGF-AB, PDGF-BB has been
reported (product information Hoffmann-La
Roche).
Assay of ® broblast proliferation
A human lung ￿broblast cell line was obtained
from the American Type Culture Collection
(WI-38, derived from normal embryonic lung
tissue of a caucasian female) and grown in Basal
medium (Eagle) (BME) according to standard
protocols. Only early passage cell cultures (days
15± 35, split ratio 1:2 once weekly) were used
in these experiments. Fibroblasts (WI-38) were
seeded at subcon￿uent density of 0 13
106 cells/ml (medium BME, 10% FCS added)
into 96-well ￿at bottom microtitre plates (0.1 ml
per well, Greiner, Germany) and cultivated for
24 h. After a 1 h ‘washout period’ to reduce or
remove FCS, BME medium without or with FCS
0.4% , and pleural effusions or cytokines (TGF-
b1 at 3 ng/ml, human, expressed in Escherichia
coli, Sigma Chemicals, USA; TNFa at 100 ng/ml,
human, recombinant, Boehringer, Mannheim,
Germany) as well as 1% antibiotics (penicillin
100 U/ml, streptomycin 100 U/ml, amphotericin
0.25 mg/ml)) were added. In respective experi-
ments, medium was supplemented with pent-
oxifylline (Rentylin, Dr Rentschler, Laupheim,
Germany, at 50 and 100 mg/ml). Medium was
removed completely after 72 h, and 100 ml of
the tetrazolium salt MTT (dimethylethimazol-
diphenyltetrazolium bromide, Sigma, dissolved
in PBS at 5 mg/ml) was added. MTT is con-
verted by mitochondria of living cells to the
blue coloured substance formazan, and the
amount of formazan produced is proportional
to the number of cells present.21 The optical
density was determined in an ELISA-reader at a
wavelength of 550 nm.
Experiments were done six-fold; important
results have been con￿rmed by counting the
cells in a haemocytometer (Coulter counter,
after preparation of the cell nuclei).
Assay of collagen synthesis by in vitro
cultured ® broblasts
Experiments using TGF-b or TNFa as stimulant
were done in quadruplicate, and all others in
duplicate. Pleural effusions of seven patients
were investigated regarding stimulation of col-
Table 1. Pertinent clinical features of the patients investigated
Diagnosis:
effusions occurred due
n Sex Age
(mean, range)
No. of patients with pleural thickenings,
ILO-grade
to: 0 1a 1b 1c 2a 2b 2c 3a 3b 3c
Congestive heart failure 17 7f 75 transudates 15 2 ± ± ± ± ± ± ± ±
10m (56± 89)
Parapneumonic
neutrophil-rich 5 2f; 3m 40 exudates
macrophage-rich 7 2f; 5m (24± 61) exudates 4 2 ± ± 1 ± ± 2 1 2
Empyema
streptococcus
pneumoniae: n 1 68
not identi® ed: n 4 5 5m (57± 75) exudates ± 1 ± 2 1 ± ± ± ± 1
Tuberculosis 43
15 5f; 10m (26± 74) exudates 1 5 1 2 2 1 1 ± ± 2
Forty-nine patients were enrolled in the study. 3± 6 months after diagnosis, pleural thickenings were found in follow-up examinations and
classi® ed 0± 3c according to the international classi® cation of radiographs of pneumoconioses (ILO). ILO 0 and ILO 1a were designated as
restitutio ad integrum. The primary site of disease being the pleura, neutrophil-rich ¯ uids were designated empyema to differentiate them
from parapneumonic neutrophil effusions.
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line (Rentylin, Dr Rentschler, Laupheim, Ger-
many, at 50 mg/ml).
Principle of the assay is the incorporation of
[3H]-proline into proteins and its hydroxylation
to [3H]-hydroxyproline in collagenous proteins
as outlined in Ref. 22. The method was adapted
such that non-incorporated radioactivity was
removed by ultra￿ltration instead of dialysis.
Brie￿y, ￿broblasts (WI-38) were grown in 24-
well ￿at bottom microtitre plates to visual
con￿uency and incubated in the presence of
50 mg/ml ascorbate, pleural effusions at a ￿nal
dilution of 1:5, or cytokines TNFa or TGF-b
diluted in medium supplemented with 0.4%FCS
(TNFa: human, recombinant, Boehringer, Mann-
heim, Germany; TGF-b1: human, expressed in
E. coli, Sigma Chemicals, USA), and 10 mCi
[3H]-proline/ml medium (L-[2,3-3H]-proline, Du-
pont, USA). After 24 h, cell pellets as well as
cell-free supernatants were harvested, freeze-
thawed three times, pelleted by centrifugation,
and the supernatant was washed four times and
ultra￿ltrated (centrifugal concentrators Micro-
sep Filtron, Karlstein, Germany, molecular
weight cutoff 10 K; aqua dest. supplemented
with 0.3 ml/ml phenylmethansulphon￿uorid
(PMSF), proteinase-inhibitor, Roth, Germany).
Subsequently, samples were resuspended in 6 N
HCl (Merck), hydrolysed (1108 C, 24 h), dried in
a vacuum-desiccator, and the amounts of [3H]-
proline and [3H]-hydroxyproline were deter-
mined by automated amino acid analysis. Colla-
gen concentrations were calculated according
to the method of Wiestner et al.22 Collagen
synthesis was expressed as percentage of colla-
gen of generated total protein and as radio-
labelled hydroxyproline per cell.
Statistics
The data is provided in means SEM unless
otherwise stated. Variance signi￿cance was
calculated by means of the Mann± Whitney U-
test, Spearman’s rank correlation test and Wil-
coxon’s signed rank test. For comparisons, P
values , 0 05 were adopted as signi￿cant.
Results
TGF-b, TNFa, and TNF-receptor p55
in pleural effusions
W e found a signi￿cant positive correlation be-
tween the concentrations of TGF-b1 and the
extent of pleural thickenings classi￿ed accord-
ing to ILO as outlined in Fig. 1 (coef￿cient of
correlation: 0.54; P, 0 005). Assuming a cutoff
at TGF-b 100 ng ml and de￿ning pleural
thickenings ILO 0 and 1a to be a restitutio ad
integrum, the sensitivity of TGF-b measure-
ments to detect risk of pleural ￿brosis was 75%
and speci￿city was 80% .
Table 2 provides data on TGF-b, TNFa, and
0 1a 1b 1c 2a 2b 2c 3a 3b 3c
extent of pleural thickenings (ILO)
0
200
400
600
800
1000
r 5  0.54
p ,  0.005
TGF-b 1 [ng/ml]
FIG. 1. TGF-b in pleural effusions due to infectious pleurisy.
Total TGF-b isoform 1 (that is, both inactive protein-bound
and active forms) was determined by ELISA and correlated
with pleural thickening as determined by chest X-ray
® lms or computed tomography scans, then classi® ed as ILO
0± 3c.
Table 2. Proteins in pleural effusions
Diagnosis:
effusions occurred due to:
n TGF-b1
ng/g protein
TNFa
ng/g protein
sTNF receptor
p55 ng/g
protein
Congestive heart failure 17 3.95 2.13 0.81 1.43 2.55 1.37
Parapneumonic
neutrophil-rich 5 2.38 0.75 6.73 7.77 0.78 0.71
macrophage-rich 7 1.20 0.30 0.54 0.98 0.62 0.55
Empyema 5 5.76 7.51 3.37 3.33 0.34 0.23
Tuberculosis 15 4.84 5.25 9.70 11.84 0.98 0.83
Transforming growth factor-b1 (TGF-b1), tumour necrosis factor a (TNFa), and soluble tumour
necrosis factor receptor p55 (sTNF-R) were determined in non-carcinomatous pleural effusions.
The primary site of disease being the pleura, neutrophil-rich ¯ uids were designated empyema to
differentiate them from parapneumonic neutrophil effusions. Data is given after normalization
for total protein content in pleural effusions.
122 Mediators of In¯ ammation ´ Vol 6 ´ 1997
P. Entzian et al.sTNF-R concentrations in relation to the various
diagnoses in the study population. We deter-
mined that the protein amounts in the pleural
transudates were lower than in the pleural
exudates in general. However, results varied
widely in all patients groups so that the
differences did not reach signi￿cant levels.
Effects of pentoxifylline on in vitro
® broblast proliferation stimulated by
TGF-b or TNFa
TNFa, at 100 ng/ml, proved to be a stimulant of
￿broblast proliferation (compared with the con-
trol: 38% ), and addition of pentoxifylline
nearly prevented the cells from proliferating
altogether (Fig. 2).
TGF-b proved to be a very weak stimulant of
￿broblast proliferation only when cells were
already proliferating (i.e. already stimulated by
4% FCS (TGF-b at 3 ng/ml); stimulation was,
compared with the control experiment, only
10% ). There was no effect at all on quiescent
(i.e. non-FCS stimulated) ￿broblasts. Pentoxifyl-
line reduced the TGF-b effect by 50% ,
P, 0 05 as shown in Fig. 2.
Results have been con￿rmed by counting the
cells in a haemocytometer.
Effects of pentoxifylline on in vitro
® broblast collagen synthesis
stimulated by TGF-b or TNFa
Collagen synthesis was clearly stimulated by
TGF-b. Addition of pentoxifylline, 50 or 100 mg/
ml, inhibited collagen synthesis, reducing it by
40%when stimulated with TGF-b at 3 ng/ml
(P, 0 05). Stimulation with TGF-b at 20 ng/ml
was not signi￿cantly inhibited by POF , although
a slight decrease was observed (not shown).
TNFa proved to be a weak stimulant of collagen
synthesis which pentoxifylline was capable of
inhibiting. The results were comparable when
collagen synthesis was calculated per ￿broblast.
Effects of pleural effusions on in vitro
® broblast proliferation and collagen
synthesis with and without addition
of pentoxifylline
Pleural effusions in all patient groups stimulated
in vitro ￿broblast proliferation. Pentoxifylline
inhibited proliferation signi￿cantly, P, 0 025 in
experiments using pleural effusions as stimulant
(see Fig. 4).
In vitro ￿broblast collagen synthesis was
also stimulated, varying between 3 and 12%of
total protein synthesis. Pentoxifylline inhibited
pleural effusion stimulated collagen synthesis
signi￿cantly as shown in Fig. 5 (P, 0 025).
Similar results were obtained when collagen
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FIG. 2. Effects of pentoxifylline on in vitro ® broblast pro-
liferation stimulated by TGF-b1 or TNFa. Fibroblasts (human
lung ® broblast cell line WI-38) were seeded at subcon¯ uent
density and coincubated with TGF-b (3 ng/ml) or TNFa
(100 ng/ml) and POF (50 or 100 mg/ml). Cell proliferation
was measured after 72 h by MTT staining and calculated as
% of inhibition by POF compared with control experiment
results of stimulation by the respective cytokine alone. Both
cytokines proved to be weak stimulants of ® broblast
proliferation, which was signi® cantly inhibited by addition
of POF, 50 or 100 mg/ml. Increasing POF concentrations to
above 100mg/ml augmented inhibition of ® broblast prolif-
eration. Data is provided in means SEM. Levels of sig-
ni® cance: P , 0 05; P , 0 025. Important results have
been con® rmed by counting the cell nuclei in a haemocyto-
meter (Coulter counter, after preparation of the cell nuclei).
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FIG. 3. Effects of pentoxifylline on in vitro ® broblast colla-
gen synthesis stimulated by TGF-b1 (3 ng/ml) or TNFa
(100 ng/ml). Fibroblasts (human lung ® broblast cell line WI-
38) were investigated at con¯ uent density. Collagen syn-
thesis was determined by comparative measurement of
incorporated [3H]-proline and its hydroxylation product
[3H]-hydroxyproline and calculated as the collagen share in
percentage of total protein formation. Synthesis was stimu-
lated both by TNFa and TGF-b and was inhibited by
concurrent addition of POF at 50 or 100 mg/ml to the culture
medium. Data is provided in means SEM. Levels of
signi® cance: P , 0 05.
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did not correlate with concentrations of TGF-b,
TNFa, or s-TNF-R.
Discussion
Transforming growth factor-b (TGF-b) is consid-
ered a key cytokine, sustained synthesis of
which underlies the development of tissue
￿brosis.11 Screening pleural effusions for several
proteins considered to be involved in tissue
remodelling (namely tumour necrosis factor a
(TNFa), soluble TNF receptor p55 (sTNF-R),
and TGF-b), we found TGF-b1 to be positively
correlated with development of pleural thicken-
ings in patients with non-carcinomatous
pleurisy. Prevention and therapy of ￿brosis still
being a source of controversy, we searched for
alternatives to steroid administration and found
evidence that elevating intracellular cAMP , e.g.
with pentoxifylline, might be a promising
approach.
Our results also highlight the importance of
TGF-b in tissue repair. There are three known
isoforms of TGF-b in humans (TGF-b 1, 2 and 3)
the biological properties of which are nearly
identical.23 TGF-b is strongly chemotactic for
￿broblasts and induces these cells to secrete
extracellular matrix proteins.11 It exhibits auto-
induction potency11 and modulates the actions
of platelet-derived growth factor, ￿broblast
growth factor, interleukin-1, and TNFa in such a
manner that central role in orchestration of
tissue ￿brosis can probably be ascribed to it.23
In an animal model of bleomycin-induced pul-
monary ￿brosis, neutralizing antibodies to TGF-
b isoforms 1 and 2 were able to attenuate the
￿brosing processes.24 The TGF data presented
in this study were obtained from ELISA tests on
TGF-b. The decision to use ELISAwas methodo-
logical: bioassays to determine bioactive TGF-b
in pleural effusions did not reveal reproducible
data.
Since we were looking for pleural ￿brosis
markers, this turned out to be a crucial
decision, since it provided an explanation of
why TGF-b might indeed indicate the course of
disease: the data includes both active and latent,
inactive TGF-b. The physiological function of
latent, inactive TGF-b is currently the subject of
intensive investigations. It appears likely that
not only synthesis of TGF-b, but in particular its
activation and deactivation, constitutes a major
controlling step in tissue remodelling and that,
for instance, activated macrophages might
create micro-environments at the site of disease
that could contribute to activation of latent
TGF-b. High concentrations of latent TGF-b are
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FIG. 4. Effect of pentoxifylline at 50 mg/ml on in vitro
® broblast proliferation, stimulated by fetal calf serum or by
pleural effusions, with and without addition of pentoxifyl-
line. Experiments were done six-fold. Effusions occurred
due to: heart failure, patients 1 and 2; parinfectious pleurisy,
patients 3, 4 and 5; tuberculosis, patients 6 and 7. Fibro-
blasts (human lung ® broblast cell line WI-38) were seeded
at subcon¯ uent density and coincubated with fetal calf
serum (FCS) or pleural effusions and POF. Cell proliferation
was measured after 72 h by MTT staining and determina-
tion of the optical density in an ELISA-reader. Results were
con® rmed by direct cell counting in a haemocytometer. It
was proved that pentoxifylline inhibits the activation of
® broblasts by pleural effusions (P , 0 025) or FCS. This is
considered important since both materials, being natural
¯ uids and containing a variety of mediators, probably
provide a most appropriate milieu to in vitro study of
® brogenesis.
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FIG. 5. Effect of pentoxifylline on in vitro ® broblast collagen
synthesis, stimulated by fetal calf serum or pleural effu-
sions, with and without addition of pentoxifylline. Fibro-
blasts (human lung ® broblast cell line WI-38) were
investigated at con¯ uent density. Collagen synthesis was
determined by comparative measurement of incorporated
[3H]-proline and its hydroxylation product [3H]-hydroxypro-
line and calculated as the collagen share in % of total
protein formation. For further details, see legend of Fig. 4.
Pentoxifylline inhibited ® broblast activation by pleural effu-
sions (P , 0 025). Bars represent means of experiments
done in duplicate, error bars the ranges of individual
results.
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The correlation between TGF-b and pleural
thickenings occurring months later opens up
perspectives for prevention and therapy of
pleural ￿brosis: inhibition of TGF-b might be
desirable since it is likely that TGF-b is causally
involved in ￿brogenesis. Further, TGF-b might
prove to be a tool for estimating pleural ￿brosis
risk, although this aspect will have to be
addressed in the context of a larger study
population.
The poor correlations of TNFa and its soluble
receptor sTNF-R p55 with diagnosis or course
of disease is not surprising when one considers
their brief half-lifes.26,27 This elucidates two
general concerns of ex vivo investigations in
that the time of sample-drawing after onset of
disease is a matter of chance and studying a
single probe does not allow for assessment of
future developments unless a longitudinal dis-
ease marker is used. Although sustained TNF
synthesis might be of importance in chronic
￿brosis, TNF certainly is no marker for chronic
developments, but rather a pro-in￿ammatory
cytokine that is activated by multiple mechan-
isms other than chronic ￿brosing in￿ammation.
In a search for ￿brosis-modulating drugs, we
found pentoxifyllin to inhibit in vitro human
lung ￿broblast (WI-38) proliferation and differ-
entiation subsequent to various stimuli as
shown in Figs 2± 5. The POF concentrations
used to cause inhibition are comparable with
those used to inhibit in vitro TNFa formation:
oral or i.v. administration of POF in recom-
mended doses causes a similar reduction in TNF
synthesis, as do 50 mg/ml POF in the in vitro
system.28
Pentoxifylline also in￿uences many of the
known contributors to ￿brogenesis: acute lung
injury induced by chemicals and in￿ammatory
mediators is attenuated.29 Pentoxifylline seems
to be protective of pneumocyte function.30 It
inhibits the formation of free radicals effect-
ively31 as well as formation and action of TNFa,28
and injury of lungs perfused with human
neutrophils.32 Pentoxifylline inhibits in vitro
￿broblast proliferation driven by different stimu-
li (fetal calf serum,18 platelet-derived growth
factor,19 tumour necrosis factor a 14), and inhi-
bits synthesis of several ￿broblast products like
collagen, glycosaminogylcans and ￿bronec-
tin.14,18 Pentoxifylline also augments in vitro
collagenase production by ￿broblasts.18
Our own data add that (1) TGF-b is most
likely a relevant cytokine in pleural ￿brosis; (2)
pentoxifylline inhibits the effect of transforming
growth factor-b on ￿brogenesis; (3) the effects,
not only of selected cytokines, but even of
￿uids containing a complex heterogeneity of
mediators like pleural effusions, can be inhib-
ited by pentoxifylline in concentrations easily
attainable in vivo. This is important since,
although steroids have been administered in
￿brosis for a long time, whether they exert
direct inhibitory in￿uence on ￿broblasts re-
mains controversial: the in vitro data, at least,
depend heavily on the culturing methods em-
ployed.33 Thus pentoxifylline may exhibit an
advantage in that it inhibits not only in￿amma-
tory mediators (as do corticosteroids) but ￿bro-
genesis as well. The inhibition of TGF-b-driven
collagen production by pentoxifylline deserves
special emphasis since, in a rat model of
bleomycin-induced pulmonary in￿ammation,
raised levels of TGF-b1 synthesis by alveolar
macrophages was not suppressed by high-dose
steroid treatment.34 This might be one line of
explanation for the limited ef￿cacy of steroid
treatment in idiopathic pulmonary ￿brosis.
In conclusion, we suggest that xanthines—
especially pentoxifylline—might be effective in
prevention and therapy, not only of pleural
￿brosis but of other ￿brosing disorders as well.
There are many results which seem perfectly
suited to the actions of xanthines and the
physiopathology of ￿brosis. We feel that suf￿-
cient evidence now exists to propose pentoxi-
fylline for a prospective therapeutic inter-
vention study in human disease.
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